Apogenix GmbH
General information
Apogenix GmbH
Im Neuenheimer Feld 584
69120 Heidelberg, Baden-Württemberg
Germany
Contact person: Patrick Fuchs, VP Business and Corporate Development
Company main phone: +49 (6221) 586080
Company main fax: +49 (6221) 5860810
Website: https://www.apogenix.com
Im Neuenheimer Feld 584
69120 Heidelberg, Baden-Württemberg
Germany
Contact person: Patrick Fuchs, VP Business and Corporate Development
Company main phone: +49 (6221) 586080
Company main fax: +49 (6221) 5860810
Website: https://www.apogenix.com
| Year founded: | 2005 |
| Source of foundation: | Spin-off from public institution / NPO |
| Name of foundation source: | German Cancer Research Center, Heidelberg |
Corporate description / mission:
Apogenix is a private company developing innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company’s pipeline of immunotherapy drug candidates targets different tumor necrosis factor receptor (TNFR) superfamily-dependent signaling pathways in order to restore the anti-tumor immune response in cancer patients and reduce lymphopenia and inflammatory cell death in patients with viral infections. Checkpoint inhibitor asunercept, the company’s lead immunotherapy candidate, is in late-stage clinical development for COVID-19 and glioblastoma with PRIME (PRIority MEdicines) designation by the European Medicines Agency for the treatment of glioblastoma. Based on its proprietary technology platform for the construction of novel TNF superfamily receptor agonists, Apogenix develops CD40 and GITR receptor agonists for cancer immunotherapy. The TRAIL receptor agonist program was out licensed to AbbVie and is currently in clinical phase I trials.
Apogenix is a private company developing innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company’s pipeline of immunotherapy drug candidates targets different tumor necrosis factor receptor (TNFR) superfamily-dependent signaling pathways in order to restore the anti-tumor immune response in cancer patients and reduce lymphopenia and inflammatory cell death in patients with viral infections. Checkpoint inhibitor asunercept, the company’s lead immunotherapy candidate, is in late-stage clinical development for COVID-19 and glioblastoma with PRIME (PRIority MEdicines) designation by the European Medicines Agency for the treatment of glioblastoma. Based on its proprietary technology platform for the construction of novel TNF superfamily receptor agonists, Apogenix develops CD40 and GITR receptor agonists for cancer immunotherapy. The TRAIL receptor agonist program was out licensed to AbbVie and is currently in clinical phase I trials.
State of ownership: Private / independent
Headquarters: HQ: Yes
Headquarters: HQ: Yes
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 4 | |
| Phase I: | 1 | |
| Phase III: | 2 |
Description of products:
Asunercept
Eftozanermin-alpha
Asunercept
Eftozanermin-alpha
Technology used:
HERA-Ligand Technology
HERA-Ligand Technology
Collaborations & Clients
Partnering strategy / collaborations:
Apogenix is exploring partnerships with pharmaceutical and biotechnology companies as well as collaborations with leading academic institutions in order to advance the preclinical and clinical development and commercialization of its proprietary drug candidates targeting members of the TNF superfamily and TNF receptor superfamily.
Apogenix is exploring partnerships with pharmaceutical and biotechnology companies as well as collaborations with leading academic institutions in order to advance the preclinical and clinical development and commercialization of its proprietary drug candidates targeting members of the TNF superfamily and TNF receptor superfamily.
© 2024 Biotechgate by Venture Valuation